

22 September 2015



Genetic Signatures launches North America Commercial Operations

- **Key appointment to drive North America Market Entry**
- **Complements Global Strategy for Product Commercialisation**

Sydney, Australia, 22 September 2015: Molecular diagnostics company Genetic Signatures (ASX: GSS) today announced the appointment of Patrick Noland to Executive VP, US Operations.

“We are thrilled to bring Pat on board as we launch US commercial operations for our molecular diagnostics platform,” said Genetic Signatures’ Chief Executive Officer, John Melki, PhD. “Pat’s decades of experience in the commercialisation of advanced biological testing services are a perfect fit for our US strategy as we introduce our recently listed FDA solution to the market.”

Prior to joining Genetic Signatures, Mr. Noland was the CEO of StrataDX, an anatomic pathology laboratory based in Lexington, Massachusetts. Prior to his tenure at StrataDX, Mr. Noland spent 17 years in sales leadership roles at Laboratory Corporation of America® Holdings (LabCorp®, NYSE:LH), a clinical-laboratory company with over \$5 billion in annual revenue. In his last role at LabCorp, Pat served as Senior Vice President responsible for developing and implementing a new partnerships-focused hospital strategy, designed to expand the available US market. He holds a MBA from Kennesaw State University in Georgia and a BSc from the University of Georgia in Athens.

“Rapid and comprehensive detection of pathogens is an important strategy in reducing the spread of infectious disease,” said Mr. Noland. “Dr. Melki and the outstanding Genetic Signatures team have built a truly transformative molecular diagnostics platform with the highest levels of scientific credibility. Having participated as a board member since 2014, my confidence in the technology and the team led me to the decision to dedicate my efforts to leading the company’s US commercialisation.”

Mr. Mike Aicher, President of Genetic Signatures US Ltd. added, “We are delighted that Pat has joined our team and look forward to supporting him as he builds our US commercial operations. Pat’s deep commercialisation expertise, coupled with the world-class team assembled by Genetic Signatures, will contribute greatly to reducing the spread of infection in the US health care system as they implement Genetic Signatures based testing.”

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Company	Media and Investor Relations
John Melki Chief Executive Officer john@geneticsignatures.com T: +61 2 9870 7580	Peter Taylor Investor Relations peter@nwrcommunications.com.au T: +61 412 036 231

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3Base™**. Founded in 2001 by the late Dr Geoffrey Grigg, the former Chief of Molecular Biology at CSIRO, Genetic Signatures has released a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the **EasyScreen™** brand. MDx is a modern technique increasingly used by hospitals and pathology laboratories to detect specific sequences of the genome, the DNA or RNA that define an organism. Genetic Signatures' proprietary MDx **3Base™** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening. As the spread of infectious diseases around the world continues to grow, the Company plans to launch additional products for the detection of pathogens associated with MRSA, sexual health infections, tuberculosis and meningitis.